Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-T for Relapsed/Refractory Multiple Myeloma
NCT06581640Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Sep 2024
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-BCMA CAR-T cells in multiple myeloma (MM), sponsored by First Affiliated Hospital of Xiamen University. Started Sep 2024; status: recruiting.
02
Drugs
anti-BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06581640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581640.